Enteral Feeding Tubes Market

Executive Summary

Enteral Feeding Tubes Market was valued at US $3.74 billion in 2021 and is projected to grow at 6.72% CAGR over the forecast period to reach US $5.52 billion by 2027. Enteral Feeding Tubes Market represented US $0.46 billion opportunity over 2019-2021 and estimated to create US $1.78 billion opportunity in 2027 over 2021.

Enteral Feeding Tubes from Consainsights analyses the Enteral Feeding Tubes Market in the Life Sciences industry over the forecast period to 2027.

Enteral Feeding Tubes research report from Consainsights outlines the detailed strategic analysis, trends, market opportunities, growth prospects, industry and market challenges and sustainable solutions to sustain in the competitive environment.

Enteral Feeding Tubes segmentation includes Product, Patient Type, Application, End User and Geography.

Based on the Product, the Enteral Feeding Tubes analysis covers Nasoenteral Feeding Tube, Enterostomy Tube, Oroenteric Tube.

In Product segment, Nasoenteral Feeding Tube segment has highest cagr growth of 5.95%.

Based on the Patient Type, the Enteral Feeding Tubes analysis covers Adults, Pediatric.

In Patient Type segment, Adults segment has highest cagr growth of 5.95%.

Based on the Application, the Enteral Feeding Tubes analysis covers Oncology, Neurology, Gastroenterology, Metabolic Disorders, Hepatology, Other Applications.

In Application segment, Oncology segment has highest cagr growth of 5.95%.

Based on the End User, the Enteral Feeding Tubes analysis covers Hospitals, Ambulatory Surgical Centers, Other End Users.

In End User segment, Hospitals segment has highest cagr growth of 5.95%.

Based on the region, the Enteral Feeding Tubes analysis covers North America, Europe, Asia-Pacific, Middle-East & Africa, Latin America.

Key companies operating in the market include Avanos Medical Inc., Cardinal Health, Fresenius Kabi AG, B Braun Melsungen AG, ENvizion Medical Inc., Applied Medical Technology Inc., Vygon, Beckton, Dickinson and Company, Boston Scientific Corporation, CONMED Corporation, Cook Medical and so on. This report covers the detailed analysis of the company profiles such as business segments, product portfolio, key brand insights and growth strategies adopted, company SWOT and Strategy analysis along with the financial analysis and analyst insights on the key companies operating in this market.

Market Overview

Definition & Scope

The base currency considered was the US Dollar (USD). Conversion of other currencies to USD was considered on the basis of the average exchange rate for the respective review-period years. The exchange rate conversion for forecast period was determined according to the base year’s conversion rates.

The base year was identified based on the availability of annual reports and secondary information. The base year considered for this study is 2027.

The review period considered for this study is from 2018-2027. The CAGR is for the forecast period, 2022-2027.

Market size estimations for the forecast years were in real terms. Inflation is not part of the pricing, and the average selling price (ASP) was kept constant throughout the forecast period for each country.

Distribution of primary interviews conducted was based on the regional share of the market and the presence of key players in each region.

As a result of data triangulation through multiple methodologies and approaches, the weighted averages of resulting estimates were considered to be the final values.

Currency, Year & Forecast

The currency used in this report is USD, with the market size indicated in terms of USD million/billion.

For companies reporting their revenues in USD, the revenues were taken from their respective annual reports/SEC filings.

For companies reporting their revenues in other currencies, the average annual currency conversion rates were used for a particular year to convert the value to USD Market Definition.

Product

Introduction

In 2021, Nasoenteral Feeding Tube segment has the highest revenue of US $1.95 billion and is expected to grow at CAGR of 5.95% by 2027 Nasoenteral Feeding Tube segment has highest cagr growth of 5.95%.

Nasoenteral Feeding Tube

Nasoenteral Feeding Tube segment was valued at US $1.71 billion in 2019 and is projected to grow at 5.95% CAGR over the forecast period to reach US $2.88 billion by 2027. Nasoenteral Feeding Tube segment represented US $0.24 billion opportunity over 2019-2021 and estimated to create US $0.93 billion opportunity in 2027 over 2021.

Enterostomy Tube

Enterostomy Tube segment was valued at US $1.32 billion in 2019 and is projected to grow at 5.95% CAGR over the forecast period to reach US $2.22 billion by 2027. Enterostomy Tube segment represented US $0.18 billion opportunity over 2019-2021 and estimated to create US $0.72 billion opportunity in 2027 over 2021.

Oroenteric Tube

Oroenteric Tube segment was valued at US $0.25 billion in 2019 and is projected to grow at 5.95% CAGR over the forecast period to reach US $0.42 billion by 2027. Oroenteric Tube segment represented US $0.03 billion opportunity over 2019-2021 and estimated to create US $0.13 billion opportunity in 2027 over 2021.

Patient Type

Introduction

In 2021, Adults segment has the highest revenue of US $2.36 billion and is expected to grow at CAGR of 5.95% by 2027 Adults segment has highest cagr growth of 5.95%.

Adults

Adults segment was valued at US $2.08 billion in 2019 and is projected to grow at 5.95% CAGR over the forecast period to reach US $3.49 billion by 2027. Adults segment represented US $0.29 billion opportunity over 2019-2021 and estimated to create US $1.13 billion opportunity in 2027 over 2021.

Pediatric

Pediatric segment was valued at US $1.20 billion in 2019 and is projected to grow at 5.95% CAGR over the forecast period to reach US $2.03 billion by 2027. Pediatric segment represented US $0.17 billion opportunity over 2019-2021 and estimated to create US $0.65 billion opportunity in 2027 over 2021.

Application

Introduction

In 2021, Oncology segment has the highest revenue of US $1.45 billion and is expected to grow at CAGR of 5.95% by 2027 Oncology segment has highest cagr growth of 5.95%.

Oncology

Oncology segment was valued at US $1.28 billion in 2019 and is projected to grow at 5.95% CAGR over the forecast period to reach US $2.15 billion by 2027. Oncology segment represented US $0.18 billion opportunity over 2019-2021 and estimated to create US $0.69 billion opportunity in 2027 over 2021.

Neurology

Neurology segment was valued at US $0.80 billion in 2019 and is projected to grow at 5.95% CAGR over the forecast period to reach US $1.35 billion by 2027. Neurology segment represented US $0.11 billion opportunity over 2019-2021 and estimated to create US $0.44 billion opportunity in 2027 over 2021.

Gastroenterology

Gastroenterology segment was valued at US $0.54 billion in 2019 and is projected to grow at 5.95% CAGR over the forecast period to reach US $0.90 billion by 2027. Gastroenterology segment represented US $0.07 billion opportunity over 2019-2021 and estimated to create US $0.29 billion opportunity in 2027 over 2021.

Metabolic Disorders

Metabolic Disorders segment was valued at US $0.35 billion in 2019 and is projected to grow at 5.95% CAGR over the forecast period to reach US $0.60 billion by 2027. Metabolic Disorders segment represented US $0.05 billion opportunity over 2019-2021 and estimated to create US $0.19 billion opportunity in 2027 over 2021.

Hepatology

Hepatology segment was valued at US $0.16 billion in 2019 and is projected to grow at 5.95% CAGR over the forecast period to reach US $0.27 billion by 2027. Hepatology segment represented US $0.02 billion opportunity over 2019-2021 and estimated to create US $0.09 billion opportunity in 2027 over 2021.

Other Applications

Other Applications segment was valued at US $0.15 billion in 2019 and is projected to grow at 5.95% CAGR over the forecast period to reach US $0.25 billion by 2027. Other Applications segment represented US $0.02 billion opportunity over 2019-2021 and estimated to create US $0.08 billion opportunity in 2027 over 2021.

End User

Introduction

In 2021, Hospitals segment has the highest revenue of US $1.88 billion and is expected to grow at CAGR of 5.95% by 2027 Hospitals segment has highest cagr growth of 5.95%.

Hospitals

Hospitals segment was valued at US $1.65 billion in 2019 and is projected to grow at 5.95% CAGR over the forecast period to reach US $2.78 billion by 2027. Hospitals segment represented US $0.23 billion opportunity over 2019-2021 and estimated to create US $0.90 billion opportunity in 2027 over 2021.

Ambulatory Surgical Centers

Ambulatory Surgical Centers segment was valued at US $1.35 billion in 2019 and is projected to grow at 5.95% CAGR over the forecast period to reach US $2.27 billion by 2027. Ambulatory Surgical Centers segment represented US $0.19 billion opportunity over 2019-2021 and estimated to create US $0.73 billion opportunity in 2027 over 2021.

Other End Users

Other End Users segment was valued at US $0.28 billion in 2019 and is projected to grow at 5.95% CAGR over the forecast period to reach US $0.47 billion by 2027. Other End Users segment represented US $0.04 billion opportunity over 2019-2021 and estimated to create US $0.15 billion opportunity in 2027 over 2021.